0001104659-20-088112.txt : 20200730 0001104659-20-088112.hdr.sgml : 20200730 20200730071438 ACCESSION NUMBER: 0001104659-20-088112 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200730 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200730 DATE AS OF CHANGE: 20200730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 201059174 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2026039-1_8k.htm FORM 8-K
0001739104 false 0001739104 2020-07-30 2020-07-30 0001739104 us-gaap:CommonStockMember 2020-07-30 2020-07-30 0001739104 elan:TangiblePercentEquityUnitsMember 2020-07-30 2020-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): July 30, 2020

 

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

 

Indiana  001-38661  82-5497352

(State or other jurisdiction of

incorporation)

  (Commission
File Number)		 

(I.R.S. Employer

Identification No.)

 

2500 Innovation Way

Greenfield, Indiana

(Address of principal executive offices)

 

46140

(Zip Code)

 

Registrant’s telephone number, including area code: (877) 352-6261

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

Trading Symbol(s)

Name of each exchange on which registered:

Common Stock, no par value ELAN New York Stock Exchange
5.00% Tangible Equity Units ELAT New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02Results of Operation and Financial Condition.

 

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated July 30, 2020, announcing the results of operations for the second quarter ended June 30, 2020, for Elanco Animal Health Incorporated.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
99.1   Press release issued by Elanco Animal Health Incorporated dated July 30, 2020.
104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 Elanco Animal Health Incorporated
     
Date:  July 30, 2020 By: /s/  Michael-Bryant Hicks
    Name: Michael-Bryant Hicks

 

   Title: Executive Vice President, General Counsel and Corporate Secretary

 

 

 

 EX-99.1 2 tm2026039d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE

 

Investor Contact: Tiffany Kanaga (302) 897-0668 or kanaga_tiffany@elanco.com

 

Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen_parr_dekker@elanco.com 

 

Elanco Animal Health Reports 2020 Second Quarter Results

 

•Total Revenue for the second quarter was $586.3 million, a decrease of 25 percent. On a constant currency basis, Total Revenue declined 23 percent primarily due to a reduction in channel inventory and lower demand resulting from the COVID-19 pandemic.

 

•Earnings per share (EPS) was $(0.13) (reported), or $0.09 (adjusted).

 

•Cash and cash equivalents improved to $1.4 billion as of June 30, 2020, as a result of disciplined operating and capital expense management, improved receivable terms, and the sale of our Australia facility.

 

•Bayer Animal Health acquisition remains on track to close at the beginning of August; Antitrust, financing, and pre-close integration milestones are complete.

 

•Third Quarter 2020 Revenue expected to be between $660 and $710 million for legacy Elanco, excluding revenue from divestitures and with continued impact from the COVID-19 pandemic, primarily in livestock.

  

GREENFIELD, Ind. (July 30, 2020) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020. The performance reflects the reduction of channel inventory and lower levels of demand resulting from the COVID-19 pandemic. Elanco's innovation, portfolio, and productivity strategy continues to be the focus, and its long-term industry fundamentals and durability remain intact.

 

"Our team has diligently navigated the challenges during the second quarter. While our performance was significantly affected by actions to reduce channel inventory and by pandemic-related impacts, our efforts are already yielding results, including better competitive positioning and greater financial flexibility," said Jeff Simmons, president and chief executive officer at Elanco. "With a disciplined focus on execution, we have completed the channel inventory reduction in line with expectations, delivered 2 percent price growth across the portfolio, reaccelerated growth of our innovation portfolio driven by increased market share for recent companion animal launches, and effectively managed operating expenses and cash during this volatile time. Additionally, we have completed all activities necessary to close the Bayer Animal Health transaction in the coming days."

 

In the second quarter, Elanco completed the previously communicated channel inventory reduction, moving to inventory levels across the world and across species that represent the minimum necessary to allow our distributors to maintain strong service levels with their end customers. This created an approximate $100 million revenue decrease in the period, with approximately $45 million from U.S. Companion Animal, $45 million from U.S. Food Animal, and $10 million from our International business. We do not anticipate further reductions in overall channel inventory levels. Our relationships with distributor partners remain strong and mutually beneficial. Our U.S. Companion Animal distributors are key partners as we collaborate to execute portfolio campaigns and maximize each party's strengths to deliver on solid underlying demand in vet clinics.

 

As anticipated, the COVID-19 pandemic had a meaningful impact on the global business, representing an estimated headwind to revenue of approximately $75 to $85 million in the second quarter, based on changes as compared to our underlying business trends. Our global food animal products felt the majority of the impact as processing plant closures, reduced food service demand, and pressured producer economics affected all three major species. On the companion animal side, brands administered in the clinic, notably vaccines, and international markets saw the most impact in the quarter. In the U.S., veterinary clinic traffic and corresponding revenue showed recovery in the latter part of the quarter coming off historic lows in late March and early April. In international markets, vet clinic traffic levels remained depressed throughout the quarter, but began to show positive signs of recovery, notably in Europe in June. We expect that the second quarter represents the most severe impact from the pandemic for both companion animals and livestock this year.

 

 1 

 

 

Working Capital and Balance Sheet

Elanco continues to focus on driving improvements in net working capital. As part of the channel inventory reduction, payment terms for our U.S. distributors have been brought to 60 days, contributing to an improvement in receivables.

 

As of June 30, 2020, cash and cash equivalents on the balance sheet was $1.4 billion, an improvement of $185 million over the first quarter of 2020. In the quarter, we completed the sale of our Australia facility, generating $55.1 million in cash. After closing the Bayer Animal Health transaction, a new $750 million revolving credit facility will replace the existing facility. The baseline covenant EBITDA for the new facility will be calculated as the last four quarters of pro forma EBITDA, inclusive of the second quarter of 2020 for both Elanco and Bayer. This amount will be calculated in conjunction with the close of the deal.

 

Bayer Update

We remain on track to close the acquisition in the coming days. We have made significant progress since our last earnings, including:

•Gaining antitrust clearances and divestiture buyer approvals from all necessary jurisdictions, notably the European Commission and U.S. Federal Trade Commission;

 

•Finalizing antitrust clearance for the transaction in Australia, Brazil, Canada, Mexico, New Zealand and the U.K., in addition to previously announced China, Colombia, South Africa, Turkey, Ukraine, and Vietnam;

 

•Announcing the second level of senior leadership, with integration plans finalized and internal value capture targets established and in progress; and

 

•Establishing a new ERP system to house the animal health business from Bayer, that is being hosted by Tata Consultancy Services (TCS).

 

"We have completed all the necessary milestones and are ready to close the transaction," Simmons said. "Bayer's performance brings momentum into the close and we look forward to welcoming our new colleagues to the Elanco team. Through extensive collaboration between Bayer, Elanco, and TCS, we have confidence in our systems' transition plan, and we believe we are prepared and well equipped to minimize any disruption during the transition period and to quickly address any potential challenges we might face."

 

Second Quarter Reported Results:

In the second quarter of 2020, total revenue was $586.3 million, a decrease of 25 percent, or a decrease of 23 percent without the impact of foreign exchange rates, compared with the second quarter of 2019. Revenue, excluding strategic exits, was $570.4 million, a decrease of 22 percent without the impact of foreign exchange rates. Gross margin, as a percent of revenue, was 49.5 percent, a decline of 490 basis points as compared with the second quarter of 2019. Total operating expense was $222.2 million, a decrease of 18 percent compared with the second quarter of 2019. Tax benefit was $23.9 million in the second quarter of 2020. Net loss for the second quarter of 2020 was $53.2 million, or $0.13 per diluted share, compared with net income of $35.9 million, or $0.10 per diluted share, for the same period in 2019.

 

Companion Animal Disease Prevention revenue decreased 21 percent for the quarter, driven by lower volume and, to a significantly lesser extent, unfavorable impact from foreign exchange rates, partially offset by an increase in price. Without the impact of foreign exchange rates, the category decreased 20 percent. The volume decline was the result of actions taken across brands to reduce channel inventory levels as well as reduced demand for veterinary products as a result of the pandemic, primarily in U.S. vaccines and international markets. Underlying end user demand for newer generation parasiticide products grew in the quarter as compared to the same period last year.

 

 2 

 

 

Companion Animal Therapeutics revenue decreased 6 percent for the quarter, driven by lower volume and, to a significantly lesser extent, an unfavorable impact from foreign exchange rates, partially offset by an increase in price. Without the impact of foreign exchange rates, the category decreased 5 percent. The volume decline was the result of actions taken across brands to reduce channel inventory levels as well as reduced demand in veterinary products as a result of the pandemic, primarily in veterinarian-administered products and international markets, offset by continued growth of Galliprant across the globe and in alternative channels, plus the inclusion of sales for Entyce® and Nocita® as a result of the acquisition of Aratana in the third quarter of 2019.

 

Food Animal Future Protein & Health revenue decreased 10 percent for the quarter, driven by lower volume and, to a lesser extent, unfavorable impact from foreign exchange rates, partially offset by an increase in price. Without the impact of foreign exchange rates, the category decreased 6 percent. The volume decline was driven by lower levels of demand due to impacts of the pandemic on global protein markets and the unwind of anticipatory buying by direct customers in international export markets from the first quarter of 2020, partially offset by continued strong growth in the aqua portfolio.

 

Food Animal Ruminants & Swine revenue decreased 42 percent for the quarter, driven by lower volume and, to a significantly lesser extent, unfavorable impact from foreign exchange rates, partially offset by an increase in price. Without the impact of foreign exchange rates, the category decreased 40 percent. The volume decrease was driven by lower levels of demand due to the impact of the pandemic on global protein markets, most notably Optaflexx®, the unwind of anticipatory buying by direct customers in international export markets, and actions taken across brands to reduce channel inventory levels, most notably for Rumensin®. Additionally, revenue was impacted by generic competition for Rumensin® and trade pressure affecting Paylean®. These headwinds were partially offset by increased demand in China's swine market as a result of favorable producer economics and positive efforts to repopulate herds impacted by African Swine Fever in 2019.

 

Strategic Exits for this quarter represent contract manufacturing relationships which are not long-term value drivers for the company. Revenue from Strategic Exits decreased 42 percent for the quarter, and represented 3 percent of total revenue.

 

Gross profit was $290.4 million, or 49.5 percent of revenue, in the second quarter of 2020 compared with $425.6 million, or 54.5 percent, for the second quarter of 2019. Gross margin as a percent of revenue declined 490 basis points, primarily due to unfavorable product and geographic mix and deleverage of fixed manufacturing costs across a lower revenue base, partially offset by continued improvements in manufacturing productivity and price.

 

Total operating expenses decreased $47.5 million in the second quarter of 2020 compared with the second quarter of 2019. Marketing, selling and administrative expenses decreased 19 percent to $162.8 million, due to disciplined cost management across the business as our operations have moved primarily virtual, adjustments to variable pay expectations as a result of performance, and a decision to shift certain marketing expenses from the second quarter into the third quarter of 2020. Research and development expenses decreased 14 percent to $59.4 million, or 10 percent of revenue, due to disciplined cost management with less travel and fewer in-person meetings, adjustments to variable pay as a result of performance, and a decision to shift project expenses from the second quarter to the third quarter for 2020. None of the shifted expenses negatively affected the critical path of key projects.

 

Amortization of intangibles decreased $0.3 million to $49.0 million in the second quarter of 2020 as compared with the second quarter of 2019. Asset impairment, restructuring, and other special charges increased to $119.4 million in the second quarter of 2020 from $31.8 million in the second quarter of 2019. Charges recorded in the second quarter of 2020 include costs primarily related to our integration efforts, as well as external costs related to acquiring businesses, including, but not limited to, the pending acquisition of the animal health business of Bayer, costs necessary to stand up our organization as an independent company, impairment of intangible assets, and charges related to previously announced restructuring activities, partially offset by a favorable adjustment from reversals for severance programs that are no longer active.

 

Net interest expense was $24.8 million in the second quarter of 2020, compared with $20.7 million in the second quarter of 2019 as a result of net investment hedge gains that offset interest expense in the second quarter of 2019. Other-net income of $47.9 million was recorded in the second quarter of 2020, compared with expense of $3.9 million in the second quarter of 2019. Other income recorded in the second quarter of 2020 primarily consisted of the gain on the sale of land and buildings in New South Wales, Australia.

 

Second Quarter Consolidated non-GAAP Results:

 

Adjusted net income for the second quarter of 2020 was $36.1 million, compared with $101.6 million in the second quarter of 2019. Adjusted net income in the second quarter of 2020 excludes the net impact of $89.3 million of asset impairment, restructuring and other special charges and the amortization of intangible assets, net of the impact from taxes and gain from the sale of land and building in New South Wales, Australia. The decline in adjusted net income is driven by decreased revenue and gross profit. Adjusted EPS in the quarter was $0.09 per share. Adjusted EBITDA was $97.8 million in the second quarter of 2020, which represents 16.7 percent of total revenue compared with $181.1 million and 23.2 percent for the second quarter of 2019, respectively.

 

 3 

 

 

For further detail of non-GAAP measures, see the Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information table later in this press release.

 

FINANCIAL GUIDANCE

 

For the third quarter of 2020, legacy Elanco Total Revenue is expected to be between $660 and $710 million. Core Revenue, excluding Strategic Exits, is expected to be between $650 and $700 million, including our estimate of approximately $30 to $50 million in COVID-19 related headwinds. Elanco will divest a limited number of products in conjunction with the close of the Bayer Animal Health transaction. Revenue from divested products is expected to represent between $12 and $20 million for two months of the quarter and has been excluded from the total Revenue and Core Revenue estimates. 

 

WEBCAST & CONFERENCE CALL DETAILS

 

Elanco will host a webcast and conference call at 8:00 a.m. Eastern today, during which company executives will review financial and operational results and respond to questions from analysts. Investors, analysts, members of the media, and the public may access the live webcast and accompanying slides by visiting the Elanco website at https://investor.elanco.com and selecting Events and Presentations. A replay of the webcast will be archived and made available a few hours after the event in the same location on the company's website.

 

ABOUT ELANCO

 

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 6,000 employees. At Elanco, we’re driven by our vision of food and companionship enriching life - all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, statements concerning our expectations relating to the Bayer animal health acquisition, the impact of the COVID-19 pandemic on our business, 2020 outlook, our expected compliance with debt covenants, our industry and our operations, performance and financial condition, and including in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:

 

•heightened competition, including from innovation or generics;

 

•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;

 

•changes in regulatory restrictions on the use of antibiotics in food animals;

 

•the impact on our operations, the supply chain, customer demand, and our liquidity as a result of the coronavirus (COVID-19) global health pandemic;

 

•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;

 

•an outbreak of infectious disease carried by food animals;

 

 4 

 

 

•the success of our R&D and licensing efforts;

 

•our ability to complete acquisitions and successfully integrate the businesses we acquire, including the animal health business of Bayer AG (Bayer);

 

•the impact of the COVID-19 global health pandemic on our ability to achieve the anticipated revenue, earnings, accretion and other benefits associated with the acquisition of the animal health business of Bayer;

 

•misuse, off-label or counterfeiting use of our products;

 

•unanticipated safety, quality or efficacy concerns associated with our products;

 

•the impact of weather conditions and the availability of natural resources;

 

•disruption in our supply chain due to manufacturing issues experienced by our contract manufacturers;

 

•consolidation of our customers and distributors;

 

•the impact of increased or decreased sales to our channel distributors resulting in higher or lower inventory levels held by them in advance of or trailing actual customer demand, which could lead to variations in quarterly revenue results;

 

•risks related to our presence in emerging markets;

 

•changes in U.S. foreign trade policy, imposition of tariffs or trade disputes;

 

•the impact of global macroeconomic conditions; and

 

•the effect on our business resulting from our separation from Eli Lilly and Company (Lilly), including the various costs associated with transition to a standalone entity, including the ability to stand up our enterprise resource planning (ERP) system and other information technology systems.

 

For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company’s latest Form 10-K and 10-Q filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.

 

Use of Non-GAAP Financial Measures:

 

We use non-GAAP financial measures, such as revenues excluding strategic exits, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net (income) loss, adjusted EPS, adjusted EPS excluding share issuances, adjusted gross profit, adjusted gross margin and metrics excluding the impact of foreign exchange rates to assess and analyze our operational results and trends as explained in more detail in the reconciliation tables later in this release.

 

We believe these non-GAAP financial measures are useful to investors because they provide greater transparency regarding our operating performance. Reconciliation of non-GAAP financial measures and reported GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.elanco.com. The primary material limitations associated with the use of such non-GAAP measures as compared to U.S. GAAP results include the following: (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they exclude financial information and events, such as the effects of an acquisition or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring items, which could increase or decrease these measures, which investors may consider to be unrelated to our long-term operations, such as Strategic Exits. These non-GAAP measures are not, and should not be viewed as, substitutes for U.S. GAAP reported measures. We encourage investors to review our unaudited condensed consolidated financial statements in their entirety and caution investors to use U.S. GAAP measures as the primary means of evaluating our performance, value and prospects for the future, and non-GAAP measures as supplemental measures.

 

 5 

 

 

We are providing a third quarter revenue outlook for legacy Elanco without including the impact of revenues from the businesses to be acquired from Bayer. We are unable to provide the outlook on a combined company basis, or a reconciliation to the revenues that would be determined in accordance with GAAP for the combined company due to insufficient information and resulting uncertainty regarding the expected revenues from the acquired businesses.

 

Availability of Certain Information

 

We use our website to disclose important company information to investors, customers, employees and others interested in the Elanco. We encourage investors to consult our website regularly for important information about Elanco.

 

 6 

 

 

 

Elanco Animal Health Incorporated

Unaudited Condensed Consolidated Statements of Operations

(Dollars and shares in millions, except per share data)

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2020   2019   2020   2019 
Revenue  $586.3   $781.6   $1,244.0   $1,512.7 
Costs, expenses, and other:                    
Cost of sales   295.9    356.0    628.6    699.8 
Research and development   59.4    68.8    126.2    132.9 
Marketing, selling, and administrative   162.8    200.9    344.8    382.0 
Amortization of intangible assets   49.0    49.3    100.6    98.3 
Asset impairment, restructuring, and other special charges   119.4    31.8    194.2    56.7 
Interest expense, net of capitalized interest   24.8    20.7    41.3    41.5 
Other–net (income) expense   (47.9)   3.9    (46.8)   6.5 
Income (loss) before income taxes  $(77.1)  $50.2   $(144.9)  $95.0 
Income taxes   (23.9)   14.3    (42.6)   27.6 
Net income (loss)  $(53.2)  $35.9   $(102.3)  $67.4 
Earnings (loss) per share:                    
Basic  $(0.13)  $0.10   $(0.25)  $0.18 
Diluted  $(0.13)  $0.10   $(0.25)  $0.18 
Weighted average shares outstanding:                    
Basic   413.2    365.7    408.5    365.7 
Diluted   413.2    367.0    408.5    366.5 

 

7

 

 

Elanco Animal Health Incorporated

Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information

(Unaudited)

(Dollars and shares in millions, except per share data)

 

We define Adjusted Gross Profit as Total Revenue less Adjusted Cost of Sales and Adjusted Gross Margin as Adjusted Gross Profit divided by Total Revenue.

 

We define Adjusted Net Income as net income (loss) excluding amortization of intangible assets, purchase accounting adjustments to inventory, integration costs of acquisitions, severance, asset impairment, gain on sale of assets, facility exit costs and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items.

 

We define Adjusted EBITDA as net income (loss) adjusted for interest expense (income), income tax expense (benefit) and depreciation and amortization, further adjusted to exclude purchase accounting adjustments to inventory, integration costs of acquisitions, severance, asset impairment, gain on sale of assets, facility exit costs and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items.

 

We define Adjusted EPS as adjusted net income divided by the number of weighted average shares outstanding for the periods ended June 30, 2020 and 2019.

 

The following is a reconciliation of GAAP Reported for the three months ended June 30, 2020 and 2019 to Selected Non-GAAP Adjusted information:

 

   Three Months Ended June 30, 2020   Three Months Ended June 30, 2019 
   GAAP Reported   Adjusted Items (b)   Non-
GAAP (a)		   GAAP
Reported		   Adjusted
Items (b)		   Non-
GAAP (a)		 
Cost of sales (1)   $295.9   $—   $295.9   $356.0   $1.2   $354.8 
Amortization of intangible assets  $49.0   $49.0   $—   $49.3   $49.3   $— 
Asset impairment, restructuring and other special charges (2) (3)  $119.4   $119.4   $—   $31.8   $31.8   $— 
Other-net (income) expense (4)  $(47.9)  $(47.7)  $(0.2)  $3.9   $—   $3.9 
Income (loss) before taxes  $(77.1)  $120.7   $43.6   $50.2   $82.3   $132.5 
Provision for taxes (5)  $(23.9)  $(31.4)  $7.5   $14.3   $(16.6)  $30.9 
Net income (loss)  $(53.2)  $89.3   $36.1   $35.9   $65.7   $101.6 
Earnings (loss) per share:                              
basic  $(0.13)  $0.22   $0.09   $0.10   $0.18   $0.28 
diluted  $(0.13)  $0.22   $0.09   $0.10   $0.18   $0.28 
Adjusted weighted average shares outstanding:                              
basic   413.2    413.2    413.2    365.7    365.7    365.7 
diluted (6)   413.2    414.0    414.0    367.0    367.0    367.0 

 

Numbers may not add due to rounding.

 

The table above reflects only line items with non-GAAP adjustments.

 

(a)The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

 

(b)Adjustments to certain GAAP reported measures for the three months ended June 30, 2020 and 2019 include the following:

 

8

 

 

(1)2019 excludes inventory adjustments related to the suspension of commercial activities for Imrestor ($1.2 million).

 

(2)2020 excludes charges associated with integration efforts and external costs related to the acquisition of businesses, including the pending acquisition of the animal health business of Bayer, and charges primarily related to independent stand-up costs and other related activities ($111.1 million), facility exit costs and asset write-downs ($1.1 million), severance ($0.6 million), the settlement of a legal matter ($3.2 million), and the impairment of intangible assets ($3.5 million), partially offset by a favorable adjustment from reversals for severance programs that are no longer active ($0.1 million).

 

(3)2019 excludes charges associated with integration efforts and external costs related to the acquisition of businesses and charges primarily related to independent stand-up costs and other related activities ($33.1 million) and severance ($2.0 million), partially offset by a favorable adjustment from reversals for severance programs ($3.3 million).

 

(4)2020 excludes the gain on our sale of land and buildings in New South Wales, Australia ($45.6 million) and the impact of a decrease in the fair value of the Prevtec contingent consideration ($2.1 million).

 

(5)2020 and 2019 represent the income tax expense associated with the adjusted items.

 

(6)During the three months ended June 30, 2020, we reported a GAAP net loss and thus potential dilutive common shares were not assumed to have been issued since their effect is anti-dilutive. During the same period, we reported non-GAAP net income. As a result, potential dilutive common shares would not have an anti-dilutive effect, and diluted weighted average shares outstanding for purposes of calculating Adjusted EPS include 0.8 million of common stock equivalents.

 

   Q2 2020   Q2 2019 
As Reported EPS  $(0.13)  $0.10 
Cost of sales   —    0.00 
Amortization of intangible assets   0.12    0.13 
Asset impairment, restructuring and other special charges   0.29    0.09 
Other-net (income) expense   (0.12)   — 
Subtotal   0.29    0.22 
Tax Impact of Adjustments   (0.08)   (0.04)
Total Adjustments to EPS  $0.22   $0.18 
           
Adjusted EPS (1)  $0.09   $0.28 

 

Numbers may not add due to rounding.

 

(1) Adjusted EPS is calculated as the sum of As Reported EPS and Total Adjustments to EPS.

 

9

 

 

 

The following is a reconciliation of GAAP Reported for the six months ended June 30, 2020 and 2019 to Selected Non-GAAP Adjusted information:

 

  Six Months Ended June 30, 2020   Six Months Ended June 30, 2019
  GAAP
Reported		   Adjusted
Items (b)		   Non-GAAP
(a)		   GAAP
Reported		   Adjusted
Items (b)		   Non-GAAP
(a)
Cost of sales (1) (2) $ 628.6      $ 4.3      $ 624.3      $ 699.8      $ 0.6      $ 699.2   
Amortization of intangible assets $ 100.6      $ 100.6      $ —      $ 98.3      $ 98.3      $ —   
Asset impairment, restructuring and other special charges (3) (4) $ 194.2      $ 194.2      $ —      $ 56.7      $ 56.7      $ —   
Interest expense, net of capitalized interest (5) $ 41.3      $ 0.8      $ 40.5      $ 41.5      $ —      $ 41.5   
Other-net (income) expense (6) $ (46.8)     $ (47.7)     $ 0.9      $ 6.5      $ —      $ 6.5   
Income (loss) before taxes $ (144.9)     $ 252.2      $ 107.3      $ 95.0      $ 155.6      $ 250.6   
Provision for taxes (7) $ (42.6)     $ (60.2)     $ 17.6      $ 27.6      $ (28.5)     $ 56.1   
Net income (loss) $ (102.3)     $ 192.0      $ 89.7      $ 67.4      $ 127.1      $ 194.5   
Earnings (loss) per share:                      
basic $ (0.25)     $ 0.47      $ 0.22      $ 0.18      $ 0.35      $ 0.53   
diluted $ (0.25)     $ 0.47      $ 0.22      $ 0.18      $ 0.35      $ 0.53   
Adjusted weighted average shares outstanding:                      
basic 408.5      408.5      408.5      365.7      365.7      365.7   
diluted (8) 408.5      409.6      409.6      366.5      366.5      366.5   

 

Numbers may not add due to rounding.

 

The table above reflects only line items with non-GAAP adjustments.

 

(a)The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

 

(b)Adjustments to certain GAAP reported measures for the six months ended June 30, 2020 and 2019 include the following:

 

(1)2020 excludes a one-time payment to settle outstanding obligations to a contract manufacturing organization in connection with a divestiture due to the acquisition of Bayer Animal Health ($4.3 million).

 

(2)2019 excludes inventory adjustments related to the suspension of commercial activities for Imrestor ($0.6 million).

 

(3)2020 excludes charges associated with integration efforts and external costs related to the acquisition of businesses, including the pending acquisition of the animal health business of Bayer, and charges primarily related to independent stand-up costs and other related activities ($187.4 million), facility exit costs and asset write-downs ($3.0 million), severance ($1.6 million), the settlement of a legal matter ($3.2 million), and the impairment of intangible assets ($3.5 million), partially offset by a favorable adjustment from reversals for severance programs that are no longer active ($0.7 million) and the gain on the sale of our R&D facility in Prince Edward Island, Canada ($3.8 million).

 

(4)2019 excludes charges related to severance ($2.0 million), charges associated with integration efforts and external costs related to the acquisition of businesses, independent stand-up costs and other related activities ($54.0 million), and the impairment of intangible assets ($4.0 million), partially offset by a favorable adjustment from reversals for severance programs ($3.3 million).

 

(5)2020 excludes the debt extinguishment loss recorded in connection with the repayment of our existing term loan facility ($0.8 million).

 

(6)2020 excludes the gain on our sale of land and buildings in New South Wales, Australia ($45.6 million) and the impact of a decrease in the fair value of the Prevtec contingent consideration ($2.1 million).

 

(7)2020 and 2019 represent the income tax expense associated with the adjusted items.

 

(8)During the six months ended June 30, 2020, we reported a GAAP net loss and thus potential dilutive common shares were not assumed to have been issued since their effect is anti-dilutive. During the same period, we reported non-GAAP net income. As a result, potential dilutive common shares would not have an anti-dilutive effect, and diluted weighted average shares outstanding for purposes of calculating Adjusted EPS include 1.1 million of common stock equivalents.

 

10 

 

 

  YTD 2020   YTD 2019
As Reported EPS $ (0.25)     $ 0.18   
Cost of sales 0.01      0.00   
Amortization of intangible assets 0.25      0.27   
Asset impairments, restructuring and other special charges 0.48      0.16   
Other-net (income) expense (0.12)     —   
Interest expense, net of capitalized interest 0.00      —   
Subtotal 0.62      0.43   
Tax Impact of Adjustments (0.15)     (0.08)  
Total Adjustments to EPS $ 0.47      $ 0.35   
       
Adjusted EPS (1) $ 0.22      $ 0.53   

Numbers may not add due to rounding.

 

(1) Adjusted EPS is calculated as the sum of As Reported EPS and Total Adjustments to EPS.

 

For the periods presented, we have not made adjustments for all items that may be considered unrelated to our long-term operations. We believe adjusted EBITDA, when used in conjunction with our results presented in accordance with U.S. GAAP and its reconciliation to net income, enhances investors' understanding of our performance, valuation and prospects for the future. We also believe adjusted EBITDA is a measure used in the animal health industry by analysts as a valuable performance metric for investors. The following is a reconciliation of U.S. GAAP Net Income for the three and six months ended June 30, 2020 and 2019 to EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin, which is Adjusted EBITDA divided by total Revenue, for the respective periods:

 

  Three Months Ended June 30,   Six Months Ended June 30,
  2020   2019   2020   2019
Reported net income (loss) $ (53.2)     $ 35.9      $ (102.3)     $ 67.4   
Net interest expense 24.8      20.7      41.3      41.5   
Income tax expense (benefit) (23.9)     14.3      (42.6)     27.6   
Depreciation and amortization 80.9      77.2      162.4      152.4   
EBITDA $ 28.6      $ 148.1      $ 58.8      $ 288.9   
Non-GAAP Adjustments:              
Cost of sales $ —      $ 1.2      $ 4.3      $ 0.6   
Asset impairment, restructuring and other special charges 119.4      31.8      194.2      56.7   
Accelerated depreciation and amortization(1) (2.5)     —      (5.3)     —   
Other - net, (income) expense (47.7)     —      (47.7)     —   
Adjusted EBITDA $ 97.8      $ 181.1      $ 204.3      $ 346.2   
   Adjusted EBITDA Margin 16.7  %   23.2  %   16.4  %   22.9  %

 

Numbers may not add due to rounding.

 

(1) Represents depreciation and amortization of certain assets that was accelerated during the three and six months ended June 30, 2020. This amount must be added back to arrive at Adjusted EBITDA because it is included in Asset impairment, restructuring and other special charges but it has already been excluded from EBITDA in the "Depreciation and amortization" row above.

 

11 

 

 

For a reconciliation of our revenue excluding Strategic Exits to total GAAP revenue reported, please see the table below, which is a breakdown of revenue by category and the respective percent of total revenue for the same period (in millions, except percentages):

 

  Three Months Ended June 30,
  2020   2019
Companion Animal              
Disease Prevention $ 176.3      30  %   $ 223.4      29  %
Therapeutics 78.0      13  %   83.4      11  %
Total Companion Animal $ 254.3      43  %   $ 306.8      39  %
Food Animal              
Future Protein & Health $ 157.9      27  %   $ 175.8      22  %
Ruminants and Swine 158.2      27  %   271.5      35  %
Total Food Animal $ 316.1      54  %   $ 447.3      57  %
Revenue Subtotal $ 570.4          $ 754.1       
Strategic Exits $ 15.9      3  %   $ 27.5      4  %
Total Revenue $ 586.3      100  %   $ 781.6      100  %

 

Numbers may not add due to rounding.

 

  Six Months Ended June 30,
  2020   2019
Companion Animal              
Disease Prevention $ 316.6      25  %   $ 409.3      27  %
Therapeutics 143.8      12  %   164.8      11  %
Total Companion Animal $ 460.4      37  %   $ 574.1      38  %
Food Animal              
Future Protein & Health $ 337.9      27  %   $ 343.0      23  %
Ruminants and Swine 410.8      33  %   545.6      36  %
Total Food Animal $ 748.7      60  %   $ 888.6      59  %
Revenue Subtotal $ 1,209.1          $ 1,462.7       
Strategic Exits $ 34.9      3  %   $ 50.0      3  %
Total Revenue $ 1,244.0      100  %   $ 1,512.7      100  %

 

Numbers may not add due to rounding.

 

12 

 

 EX-101.SCH 3 elan-20200730.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 elan-20200730_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 elan-20200730_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Equity Components [Axis] Common Stock [Member] 5.00 Percent Tangible Equity Units [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] 5.00 Percent Tangible Equity Units Respectively. 5.00 Percent Tangible Equity Units Respectively. EX-101.PRE 6 elan-20200730_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2026039d1_ex99-1img01.jpg GRAPHIC begin 644 tm2026039d1_ex99-1img01.jpg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end XML 8 tm2026039-1_8k_htm.xml IDEA: XBRL DOCUMENT 0001739104 2020-07-30 2020-07-30 0001739104 us-gaap:CommonStockMember 2020-07-30 2020-07-30 0001739104 elan:TangiblePercentEquityUnitsMember 2020-07-30 2020-07-30 iso4217:USD shares iso4217:USD shares 0001739104 false 8-K 2020-07-30 Elanco Animal Health Incorporated IN 001-38661 82-5497352 2500 Innovation Way Greenfield IN 46140 877 352-6261 false false false false Common Stock, no par value ELAN NYSE 5.00% Tangible Equity Units ELAT NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Jul. 30, 2020
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 30, 2020
Entity File Number 001-38661
Entity Registrant Name Elanco Animal Health Incorporated
Entity Central Index Key 0001739104
Entity Tax Identification Number 82-5497352
Entity Incorporation, State or Country Code IN
Entity Address, Address Line One 2500 Innovation Way
Entity Address, City or Town Greenfield
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46140
City Area Code 877
Local Phone Number 352-6261
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, no par value
Trading Symbol ELAN
Security Exchange Name NYSE
5.00 Percent Tangible Equity Units [Member]  
Document Information [Line Items]  
Title of 12(b) Security 5.00% Tangible Equity Units
Trading Symbol ELAT
Security Exchange Name NYSE

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 3 95 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elanco.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2026039-1_8k.htm elan-20200730.xsd elan-20200730_def.xml elan-20200730_lab.xml elan-20200730_pre.xml tm2026039d1_ex99-1.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2026039-1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "elan-20200730_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2026039-1_8k.htm" ] }, "labelLink": { "local": [ "elan-20200730_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "elan-20200730_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "elan-20200730.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 1, "memberStandard": 1, "nsprefix": "elan", "nsuri": "http://elanco.com/20200730", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2026039-1_8k.htm", "contextRef": "From2020-07-30to2020-07-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://elanco.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2026039-1_8k.htm", "contextRef": "From2020-07-30to2020-07-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "elan_TangiblePercentEquityUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.00 Percent Tangible Equity Units Respectively.", "label": "5.00 Percent Tangible Equity Units [Member]" } } }, "localname": "TangiblePercentEquityUnitsMember", "nsuri": "http://elanco.com/20200730", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [], "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 16 0001104659-20-088112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-088112-xbrl.zip M4$L#!!0 ( -(Y_E#P'[#MU@, %H/ 1 96QA;BTR,#(P,#%R5R@#('"6T>V-XDNMF0DF03^ M^EO)=A(2$Y+0SER>]./[/NVN5[M*^\LT3<@#2,4$[SA^H^D0X)&(&1]VG)N^ M^[5_W.TZY,OG/]\1_+7?NRXY99#$ 3D1D=OE _&)7- 4 G(&'"350GXB/VB2 MFQ5QRA*0Y%BD60(:<*,X*2 'C0^4N.X&LC^ QT+>7'5GLB.ML\#S)I-)@XL' M.A%RK!J1V$RNKZG.U4RK.6V6O\WHYTQ%,_)?_WP\F!Q-K]C=$/C'_"*\^ZIN M:?\L#2_U4W8PO8?Q*+\=/857X\-_'Y7^-GG*QNS\F/7^WOMPV_Q>'-E6T0A2 M2O!+<-5Q%KR;[#>$''I[S:;OW9WW^A;G%,!@FC ^KH/[K5;+L[L5= 4Y#652 M2>][9CND"F;*N,O6X!E7FO+H&3[6,\(B^, K-I]!62WTL("R"AK#$DY!U!B* M!P\W$.^WW*;O[OL5/%?ND-)L1AE0%5KIA>-B/=35CQFH6D*Q54/C M@O,\K0]EK*5G>!Z"7$2!9%'%@X3R&[A0$DO("Z2()E&>;,>9FU)+*1>J&,VC M5MVP*Q@0>S,#\^4[CF*F,#KEVDC"H..80+K5Q_F)KC4P)RJ(D5YS,VWDEZ-1 M'EQ)4!FMJ*Q4#A01&4C-,*T7RD-A.M.&?KEP##'G*(=XO\+EA(;;NHP42'ZC MKSVC_TN=Q$S:ULGGR?>;/#V9';+H;ED-O'DY*.?+):.-C@NI"5^I/.O:2-$ M>R*R4FLH9N96/-UMO&5,5S2[#L8L;:9U5FA7B*9@3MG M;VK VM;X0ACL^;5$K/Q:52MOM&:UC^YNCM7:P9X-FO0FJ;+(O"B()E=:)E?\ MPS<:LYLA.UOQ+/DBD7,M'TVPC[;*VD5B-7'G*EOGR_)+;:-4J4A%FIBWVQLR MMO[IMZ,=K^1K^>"S#RK32GY>4SYD80*7("/<^':?,_UX@[5;G4,:FK>7L;SC MO(ZCH=*21OB"U#+'2LA9@@W5=(-B;O\/!-@XF(BO;7^+FG1?OW" 6 M*66\JR$U,(Q$CLI,YP9Z)D6.K_-"BR%D$]]>=>I_YDW;*SX^#O\#4$L#!!0 M ( -(Y_E P*!HU[@@ %1K 5 96QA;BTR,#(P,#&UL MU9U=<]LV%H;O=Z;_@:M>TY+LN%V[\784Q>YHFL1>RTFW>^.!2$C"& )4$+2E M?U^ 'S(_<"#*L'1H.=A%O"0 ML,5%[^O4'TW'DTG/BR1B(:*X[U?__W#/SSU[_T_?=^[(IB&Y]Y''O@3 M-N>_>%_0"I][OV&&!9)<_.)]0S361_@5H5AX8[Y:4RRQ^B)M^-P[/7J'/-]O M4.TWS$(NOMY.=M4NI5R?]_M/3T]'C#^B)RX>HJ. -ZMN*I&,HUU=@\T@^Y<6 M?T\)>SC7/V8HPIX*%HO.-Q&YZ!5:?3HYXF+1/QX,AOW_?OXT#99XA7S"=- " MW,M+Z5I,Y89G9V?]Y-O]ZXQ/^0K1 X472_=@N*D)7^%5S.-^R"YY:)OKQ51>IC" MI,#;ZV)/44S3)-&[U41>XG^ M2Y7GPNL[%6=H=FSQVJ(#XSK-I5)3\S M'XE?#P.5MN0@!KIF\ K[SP!<#83Q/> M0#0XW+UTO*MG>?K(_1UB"Z(&Y1LUF.\ZTE<5G@@,MBZWK]B]ZU[)IT7KT'O5+WV-:>VN'_7@52>I-UI J)J[1 )HW0(Q4]=H)@N,:5Z68U8H[.B;N\0 M#D \!.3GKH%XUB(DD#KZ 19.X#"*AUDT6JN?Y+ M#%SH5F95*P=B;Y0,QKS5!#N5EE^$85)O)K3%O6SI3.P-LL'XMYI8I_+&RA^! MZ(2%>/,[WMH 5$R=(6#2#2)H-:%.]=T(LD)B.R7!_L&G:NL,!*-PD$*K670J M\ YM)J'RBLQ)NE=W/PR@B#-,;/I!-*VFT:G."0NX6//"E?HQC]4YO1WST#IE M6 LZ@VF_%R"L5G/M5.TH# 6.HNP_[=W0ALA@[@P82#MX8Z_5O!O2>'P8CF.' M<1S;<;2:=T,:3P[#<>(PCA,[CE:S[Y+&L?IX+>[X$[#S #!V#45%.0BB@]0[ M4YC,;M?B1O!'DCY"M8]&I81K2$SR02X=I.=YSTD7'$W.CM32-0Y%V6#\.TC/ M,WDW/)*(_H^L]ZUX3?:NL:B+!XFTFJUG?41?T(&VJ)5,'(A[72\8ZE93?N+Y/M>3,>MV[:N5 O(V2P9BWFR;K9R$C< C9 M?>U E,M:H?!^UR,C!X?W#T&D4J4?I(A9=ET+N+MI-'4@[+!N$$&KJ>Z44Q*H M:+'%9[6Z%011<_SK=@X$'Q -1K[5K/9&8-TKL$HEDJV$^J%K<3V?0R,[;.\ MB3WB02*MIK<5D9,HBK$XE$NME'MTS"Z C%I-=:S^[TZP: T:IB MY0 #HV0PYJVFMU_XG4#Z%4G3[6K&*?R8E<'0@4488H%*'W>/G@)7*?:5<@%,$Q= 1AW<%_X#4_H[XT]L MBE'$&0[3],5VYP4HX@"=_?I!-!W<*?[&:RA*ALY0J*L&@]_!ON[I"E'Z(8Z4&Y%UC"H9.A/\NFHP M^!WLW+Y<8;%0 ^9O@C_)9?:XM@V"L8 S,&#U()0.=FA?;IY?,9$^HVHE4K-V M!X=9.L3BM)/'HD=!H#?AI*L*%B(!T(#M'>"Q1SQ(I-7T_%HNL2BN\1*!VB7; MYIA]I1R@T\@%D%$'Z7GQY1_6*;U@YP '0#08^0ZR[YMX1DEP13FRYA4%,V?B M7M4,AKV#C/L#8@\B7LM@>R-X@+&^U17MSM@&B5ZC"IQ!U=P;$&(7CUH_O]MW MND0"1]>Q3/XHD-)LO7AB*><,LKU.@*0Z><59]/S0)0X_;&_Q' N]E>4.;^0' MU=R#?9&VM[@#W [S!<172/G?]RMNJN8?U'?91O4$L#!!0 ( M -(Y_E IO0P*0@P "25 5 96QA;BTR,#(P,#&ULS9U= M;]LX%H;O%]C_P/7<[ )U'"?3'233SB!-DT$P:9*-G<[N%HN EAA'B$QZ*#FQ M__V2U(2TY9D+UI7>@_U4GQ,4A\\?O?K>A&C9\*3B-'W@_'>_@ 1&K P MHO/W@[O)\&1R>G$Q0$F*:8AC1LG[ 66#7W_YZU^0^//N;\,A.H]('!ZCCRP8 M7M ']C.ZP@MRC'XCE'"<,OXS^HSCE=S"SJ.8<'3*%LN8I$3LR Y\C-[N_8C1 M<-BCV,^$AHS?W5Z4Q3ZFZ?)X-'IY>=FC[!F_,/Z4[ 6L7W&3%*>KI"QK?[V? M_\G"W\41?3J6?\UP0I X630Y7B?1^T'EJ"^'>XS/1P?[^^/1OS]=3H)'LL## MB,J3%I!!$25+,<6-CXZ.1FIO(6THUS,>%\)LG?) M IRJ-N\\# (5\G_#0C:4FX;C@^'A>&^=A(/BY*LSR%E,;LD#4M4\3C=+P5$2 M20P&^;9'3A[,9F+.1S)^1,D("D4M !UNNH M5E8>-+)M]H;PB(5G]'6N]6A']L5WAZ=?48%JO/4J3%F*XU>9KT9:MWU%7G?& MMW'VS[3HY,GKSG0E\KO83IN6=SZ]YO,:RXV7XE/-(EFG8O@B86%2%M'2 ZLC MJ($A+[LLG06U0)M%EEJ"'RAAO(F- M+[?<3\6!HUE,Q*0@*(F^HU&:&$'H&6,#BIWL2T!Z!3B'91>7.CAO]\2E4QZ# MBC)0WO6H\&^&TS<>WZ9XMIT]0-UM+G(R@M4,&HA M(BFP2$BP-V?/HY!$&1'B@PZ"V'3_D04K:4+>&> +=6$LYF[D0EC3YSC=G2.@>FIT$=G2($56+0%QF%5)A;E*:BW)9Z9KMMHU(UI:,A]WF%0L40 MV/12XZ293\3A0VGA/,9S0R6T_;8:VFBK:.G:3B^:VN1(;^M2@Z3(;6-_)$G MHZ7L:=IJ4Y-9;WJ#R08!%8U?(#2-P3Q4M$Z[^ELRCY*4JP&HG,^T=&R WO9@ MT&I;'QV,8B_0Z>,0'#^J0:B,-M$-5EMMDQF=21J6J\(L5@ M# 0DTZ),[)2+?ZTP3PF/-YUH-)2VZ0"LZH!H,J\8,7L#,2GE/I RY9@FD>S2 M.E%I2JU?D@!F&Y!E\DCB6/Y6 #3[L[%)+;-#&Q8IZ:I M](H;T!Y(CHI >8AO\)P]RQF\F$3UK')%[Q*AANTVBDJQMR#I#GNRI,*0C'/* M4^75D Z2&DK;# %6=7HTF5?-Q'B4!CC-'YV);VY,<@]8V)J!='96&T"M<('<@,EE 08X*\0"; M_Q#,^T%34;I!IF'5#$PI\Q 7W5L7+%+O$)73%>YQNM+F;R&B],QZ8RF4;J1RQ^N5H9WFLP26X1 Y@HR]/U>$ &8:KSTJ&1( MZE F=-C^Q=,&FLK%)V"E=)E=#LPFZRS4-1[Q8#0&,+'5JK5 #KDX%7T5Q_$% M#KO(=-BNDP.( M/0*HW2' D0A"]2CW.%W0@/$EJ[Q.<8'< 1;GR3?$!R1AT3?U"YV"'"A^X1^>@+SH'7J-S\!ITIB_,*W0.=ZCP MH7MT#ONB<^@U.H>O0D,VG[,7T:CBH= ).TZH1FZW,/V@:WKJ0 MD0%RGB-#W,.BIEW7_(:SYX@&\(0:DCO!!C!M9$?3^@>0V6 71>5TN8ASCU(^ M<>_\PA0R-SU.W:2YN\DT_J%2-];9T61J]V#LENUGL!!*C82,J M-:5_P)CL=6&3Q2 1Y.X2/$=7/A@Q+G#3]EM[@FVR53ZVKN[T @63HV9^C>QN M2R9RT]B25TXPT#O4=UMK:H.ILJ4K^_QHZ*:A1CNK[[C0N/M2RTQ_\-X;O8[Z1-_^!1*HXOLS2M:/[,R/2F(J"SU=:M-HMV-XJ\8*#-F0"GAMY'J""3G6AE@>X)FY!@)<;-S?A@-HW21O8]L\3: M* 68*\7;JEDV5$K;;PL#HZT"@-I.+YK>Y*C1 M$=1:W.D@<+8.'H4U BR-,,ML#P8FD_J 4-5X 4*+L<:%2RY%A=;=THCM4#;O MGAS,G4T.YAV3@[F/DX-YW\G!W/'DH#AXENA$]%37LSB:8R !8ZO:-AHMEG5* M#%*O@(']@?U'&8*V,6YR=ZH$;I44P>?B@Z&N@,Y:]LXVFV7Z3I/("U+:G#42 M>&8I]:I9FZ7:#1VK,$I)F%DZCRBF083C,A&DZ9YZ=X@U9GJ:+_'IT/M!4C^3 M#:BRL")?8QFX3>KIYF9\]IK''R2.?Z?LA4X(3A@E878'QO39;\HIV#9;UR"U83DEA>7MYK6UI@;M1Z1TVH06G&> MYRS9SIRS**>+0%/"<9!&S^0C3G'N$*PU)+>][+/-M+[>TZ3U"*16@^ *SS)& M)KS!!5F.$]_P4S$1F[.6-]4UE?WT-PV+S0PXI<0C2$R^6O+@<%1H'1(Q6> X M_K!*(DH2>&C25':),%JL$U&3>$2$R1= A)*B0NN0B+,%X7,Q[/W&V4OZF&>E M!6L(J.T2TFJY3HI1ZA$Q;?X )E;/\DG"]35(+<,#FM7( M:>A\P@8RUV F)H&\/W/%4C1EZ"XA*'TDZ"S_0>1J1ORL'+>_P1($8FD-K$UG^/!33<^%66AM(+G#KMP;_04D:@(L0).]>"9UZ]XE-6Y"\1@NLN MND-L<=37?$%3E]X+IGJ:U,E28?7+ )8$UF>-QL,:M/F MBL(+4D!;T*2Y^LL)+C,#KF9Q%)S'#,-W96H:R_D F_:T5(!;@4<<-%U!"0"5 M$"FE0PH^8/K$5\LTV-QP%A BW^A*ROZKZZY=SVB[Y.Q4I3I3O4(]HFT7OP"' MVR)0I8PWE3',_2U ^>*ZS%7'@J?)(Q:G\7J5)G)D%?;@^^BM098?4/2H@/:8 MHB7"(P![V(0>6:A(I$+?H"P85:*=7L,EVTR')/RPN24/A,L5$%.R3C^(PSVU M7(7TB+5]A=>[.OH%7V>@%RCNZA:Z'$Q0M0 TDV^BY46@+[(0I$KYZM^&)^+H M@CY1L9\.]Q5[3N;7@'M95,'Y^W>_KZ\Y12H-7=Y,,JBD0H7!"5+HIZGQ9N]-G"^=R/E M-ONW%13@9Y-UN/T.+5?=="D^B&ULU5U1=]HV&'W? M.?L/'GTF0-*N2YJL)R%)#Z=IDP7:;GO)$;8 G0B)27* ?S\); *V)7\TW9&6 MAY2:*^F[]\J2/UMR3M\OIC1ZPD(2SLX:G8-V(\(LY@EAX[/&EW[SO-_M]1J1 M5(@EB'*&SQJ,-][__O-/D?XY_:79C*X)ILE)=,GC9H^-^+OH,YKBD^@#9E@@ MQ<6[Z"NBJ3G"KPG%(NKRZ8QBA?47ZX9/HC<'KU'4; *J_8I9PL67^]ZFVHE2 MLY-6:SZ?'S#^A.94L,<3\VN()(ZT6$R> M+"0Y:VRU.C\ZX&+<.FRW.ZT_/]WTXPF>HB9A1K08-_)2II:JMOB0._%8DD)W(5W@V/D5IY7MM,9$68_S5S6-,<:G8. MFT>=@X5,&KGX*P4%I_@>CR+SK_9NTRJF.C"NW9JVS%>M+M=]4<>Y*C01>'36 M,!!=MZ[][5';U/QJ!Z26,]TG)3%=JA&U=EJ="2PQ4RNB-_K 3A&\4+HKX22O MR+0/BTL19:!91^E$3=.KTJEN27]<([,P\D HCW?:ID9]7B!JFI:Z[97&$L<' M8_[42C#16G>.S8>F^=!L=S*%7^E##ZOFSH=2"12KO#Z*AIBN6GG0F *D];VQ MY:&-D!RN^D JFV.$9NOX,%4R/U(,-#O\8$XV;'0:H*%QJQ1M!BSBBB%O^WHN M=L-'(LXKUA]W3"UWX S1FB&AZVO&$T(W_6$D^-2F8=8@=T;-18*%'E/;[1>( MOG>'R+NB&>3$-._ZN*=#D]7]PUW"L_86;7<-J"6167'X(BM^8/^_^B7"K%=\BDBS.Z.!1Z8*ZX>5S#)0B@S MQZ\W.JHI9WW%X\=/>#I\GI/+OE1 ZSS9#!/_D1O.GE5PP!O$7B%Y!U>LH75P]BM_5# 2B/9;@Q4>\=*E?@D+E#R%K=K+UJ/^=(%,D MEGT2UX\Y92S4@1!R93=?CQ8,T**7:!YD1-9+V^J=L!:!&A)"H@QB[]&7'HNY MF/&M^^U=GNKS=]GEB7.:J"D(]2B$#'H/)3PZ=9XD6D.9_6/X=%S^5,+!3^>" M<<7!.B@O#O?SXA#N10B9=2WKH+PXVL^+([@7(637M:S]>]'5'V_%@,\M2P>L M8*@/(637-8S]N[":PV[%G>!/9+V_H,Z*4@FH'^$DW6[N_DW)KBD@YT6.A)H0 M3@)>S=6_^'=<*D3_)K.ZB]MJ/-2(<%)Q%V\_MV'77<+4AI04*U3R$A-;)UHO^?4Y) M3!1AXT_ZTE401*O%K\)!E0\A?;7S]"+[G<"F$V"=)*S6^YE-Q^)V-+*-YBX\ MU(80LM=ZWB'8T9,RQ6)?4RI*0:T)(9&%:N!GF,)QJL?.9>=P.# ;[2V#5 D% M-2"$)-;&T8O@G_E (//"C_YR.N34OONI$@B5/824U<'4B_([T51K7H! U0XA M5ZUDYW5(N5K$$\3&V+Y I1H)53V$W-7%U?-X/@:-Y^,]Q_,06!62#@[F?+:^KS6Y;)*[UAVHO+%"H"R%DODZV?O1/ M$Z)PL@[LFC#$8IT5;O9^6FY"U)>"NA)"5@S5P.,SE&^8TH^,SUD?(\D93M:) MB>LQBK4(U)H0,F40>X^^?.4TU=*)U7IC83E;+%"H#R&DQ4ZV/A?WKE?9;V:U M]3L+73;82D#=""%'AG#WNJQ18?,R./*$+Y%"69PN4VPEH*:$D$%#N'O>]"&Z M>DH;<_<*B (0:D$(:;6#J4?E^U-$Z44J=>#2.305@%#E0TBM'4P]*G\UQ6*L M1\8/@L_5)-LI[7+ 4@#J1 CY-H"Y3T<6SR]U6.\1==I1@0:_3B0<+ZR<_;Y1 M)X[-BIGUA0-+D+!8X<)#S0@A]Z[G[<6.6S7!8OL:;A62(>%:UU)?"FI-" DX M5 .?D_C6NS:<<_@.#FI".*EV%4^?FP?3(27Q->7(F3_LP*"BAY-75[#TJ/D% M8H\BG:EX>2=XC+%Y4B4W9R<@FP-6 /4IG(Q[+V5\WA5Y?D%N?Z*5D+>I6OV9 M"AVE\]Z(LQS4KW"2<8@.7J_!Y/.^1YQ<+._Q" NS]&2 %^I"-_?HOB0#%(>: M%D+ZOK1?4$L#!!0 ( -(Y_E"O60&5 M^Q0 )]W 2 =&TR,#(V,#,Y+3%?.&LN:'1M[3UK<]HZT]\SD_^@EV?Z M3#(G@,T=DO(, =+F?H$T:>?,,+X(4&-LQY(#Y->_*]D& ^:60MJ>TYS3!"QI MM=J;5KN2?/2_0<] +]BAQ#(_QN2$%$/8U"R=F)V/,9>UXX78_\J[.T==!O6@ MKDD_QKJ,V:5DLM_O)_KIA.5TDG*Q6$P.>)V85ZDTB*R7DB0Y^7AYT="ZN*?$ MB4F98FIXU,@@YM-\^+QT5%5U##)1E3\).DDG9T!#J3YN$*Z<2WJ%$U599-6L M5Y4%50FU,BDYOP@/K\:HP6!>79GC#"/$C\=W%^/J++K^N&J2.8I)VY;34QCP MD$/*QJ54/)4+ 8E3K$T @N^)CO6R%$XAGI8#.#/,F1PI+U85.J*XCJ?('?0) M!1QZ,2[)(>@.;L\%GDM":5#1I?&.HMBCRFV%JJ*B7Q !&TH8,H\?N%_+N\I/=48?-H@Y@IB$.(XV>7 MO'R,52V389/%FS"J&-*\;Q]C# ]8TM/K)&^7],$>_5\\CDX(-O02:F!VB*Z4 M'BZA@3XX1*36?>-#JO:I4KF!/WP@*!Y?M77ZI,7'UAH/L!4,< TH MF9-1J[66ZW"4ZOU6'M, #IT#<1SQR >M9;<\FVD-P)XM Z,5*O151Q, M6ZF6F!(\(%0\6P=.C>-RX\-*SZ T%[AJZ4-$V=# 'V-MT)H2DB6;H2;I094K MW$=W5D\Q#[P'!X" 0]I"/W7R$K33"06F#$L(K D6A610XHJ&':'!XBO1=6SZ M"LT?0-TKS_!XVCI@=]R"GCA6C\MY7,K'TQ*SQI]CR(2!0V^8E"(E.58>B_)1 MQFA"!V)E43X'B>0D.3A2,#U@!_P63(-* M?#8J4>%F 'Y(^ ZEKIADN$&)![8@,:!ZS"_F%OUCC!)0$>S9NU%_4QUX?5++ M=4)="A$I^41!1%](E, T!\VPX,CHZ>@YT7E)FV 'B='@R&F\>GH^R;WIQN/N MDI']^;W90&=+G\4"?"F'U@ZZ/Z!2@P'U>/LZ3-^@R5;/!MMA,EH9$!HK!]5FQGV4C.PBC%XR&K]_E^!H M+F7@<#05LT-4 ]]@4/2 V/"/2)5W,?8#YKI!WP6D,59VO*V8I)6 MF.7,BN(:-)C&,0IJJ-,:-JT>,9=UNYPNT_U& 0[*)Z@01=#DC'?@^2R!1W>4 M!!#PE_]W9 =>8$]Q.L2,,\LN(>D0<2F+*P;IF"7$]0X[A\BOHEH,C!/4BL&2 MSA: PD[NG6O@^(W2$8N(L)\9[D%.V6P&8)H_ZQ.==;D;*WV(3317+0?P]YH? M&XKVA &HI9!]$/D%P:0O')Y7,Y]XS@EK^!YP]-8^;__D7/2H4<)_W=H",F) M,43128P^ &)/55G5$1\1P"-Z!$7$LUE6 &&HK9CA_H+!9?CHCM3R_=5ILU[; MW6DT*\UZXRBICK#E+O7^[K1Y6F_L[E2N:JC^6/UGEJ@F M4$K*9HK;P'5S4K?ZX*-8=7)]=XF\6MQJ\U5L44J+J$(\7K,TET^U/)K3TD8! MD'$HY/4U?2Y=/]5(2H;5U@^O)\/]QN0UW%9(A9T%#C 5HDIY'E(#F[I^\CJXU8%X.QP9KK$$:@ MQ_I ZX+GAE%%8[Q<+J8S&T7VG>C.73.._QWF,2JT%WRO*S#M8LI0_05J[NYX MY5C?+R$@V+1B5*<4XT;X=G7/\XO6D-O38EO)#YV[N^Z;-20<^="YJPWMNKHR M'&)P1SE((#'_#N30@N]K=^H[IYIE&(I-@>G! MIREOEV/@!.!?L,.(IA@!T3SO*E@3'3$]J.B#2*<^3+JYP@T3#_J8=+J,@S#T MU<0\-2'F8VDA/)H#0E/U\DA52Y\C]>SBUOAT8PSDOK()Z\43B'QUS;#M6"]< M8";-UPIXQLJGIDX44YEKQIA>GB7K:E0=2Q+3WX=#]0D.\90+C$?%3C0[Y*[K MZD\O-_9&W*WI/GG02(ZG"[F<_,\@;F&"N$UE<.J'P#0A6HLHG:D_FXJDX;.S MPL8H/0\DDV,9(/]9G!O6]),4B!RI'O"CH2#.TM^P"FVP!EVT'=PA:E./&_9:H>F M5/0K#I2$C>=^"-MIW9T+<:[B!5V\#;&IN$64#7@K2M%AKFE-8);]9NGA&1!" M>=3[2'5&.3UN.I&GQ/MS+.2:@K%EXOXS5?LT<9=H)-;0[7K/-JPASSG\VKH\ M.5NL,< K*S&K^O[TD13>\1_/>UHS5L'#[RQ3_+":>FPN=+/8;ZSHNH,I]?]< M$!/+T6[-B?VEX=[W._)K9F-N343GL7(J*TFP/#6M%R&[Z$$9+HT[K"S>Z_Z\ M'UM.HMA2A8_73M/JFW."J(^5#":&]'R].5]SINM8^9,#JZTVSXS,X<3!3"!8 MBAJ.\*2NG1M8P8&S,2_L19XJM4Z_7_]NO-_",1K!Y2M&-7H*^+FSFC^8=5S6 M-K(=&#&Q8>+" ZRYC+SPD S,()@N\P77LH"I#XM7<[^C28W4W1L+I,[X1NP% M,9*.TZPV3J5.^^VB/D>2)WJ/E3,Y.;,L?/N+23'@OH8$\V'^',=E.T0;1W'_ M^Y]"2LX?4JAF8+MKF1B98N%P@$!C#9?[2KL[BH,5D!D=B^S#WCP)Y5:] E7G MRZ13>Z#W7X<];),-R&2XOUBYD,_/D<%]+H11>9.BC_B%!?[8#1_]HM@+.?FB M7]<,2S]7-X#\=)^Q*:XF[Y%0_$FIZW$4 M8"4+= (?L+.[H30RP5XA0,%X, RB=IY0IZ;D&4TQLN=08(@J>/VT/14N_@:4"+HH?21,% MH621"W **;RPG5[XOM4;\G=-S5_+,LN.Y*ZW!)X)JG-@T:'[])3; M9> VFPVD!^N !X/AKFF'Y:@T4;\RAJ:'D6'!R 1)Q/=2%)\ MWG& 2'P]7A8.5\QQ1.J03[UBYL-B0Q4K^RC L,(X[.[8H;T8?)L:RJ2RO@IP MO0AMP> [+_;D/*J>W*%46DI Q?W)2)_PD,;^T1]I_S%I#[R5AB4V(L/P+L$> M@E$THD7]FU6XR3>^N">#GRCJL\B^KYR/^P=9\A! @8SO[@1"+F>4N)P*R?G$ M_J*1E&>DA%?SCZ!O4]"SOJ#?.)B;2'XP26R_XS.Z<]UNSW/0&^?GWVXNOMT7 M^&GGGR7P\Y%^7\$'/.):")'EEE[.Z/'4GKJ_FAIX=?\HPC85X3A:$4XI=;&S M5!V>'H=?G6+W^/4D]\NHPPSJO[Q2I'$\LZ>MIA1^W?=6BA\'&'+KO)4/=F#M M9$?MRQ46PE\E 0%^Z[7,@@S>CVZ7RWP8GR\*9WHB3Y)(B>SD69)-!F":_%:$ M,2K .JQH7:09"J6E(!ZS>/,3MU8^S>..%\?()C(\WA$\Y?;+?_C+C-M1O.AE M@$QCV%,M8X_N_X,'S:-)L[S&@<4"!>YW"3P9:_FD",QNYHKPII]_>.?GG6CN]199-#"96KE]4KGX_SIQ,Z5/@QLP]6[ 1!CVKLIDM M5MNFM<[6X-48-)V(YV9N-@20%G MSS5LT/BMSJHV.V]^4[YF+M9)]_\8IV;M8O.7XD=Q:R9O=;9\'UXV[8Z9TGIO MG*%6YLM[FL.H_0^;/IV7XL?SPJ?IMY+L'$5P^&XLC1^_5(=($YE':/4$_C(6 M^^VGLH*$(A UD! .&!89'&H6UNY.U*G8$50>H!@W#,%- M;#;#F^&IVZVRS N6U7W:HRG2SWI%;:5'C&%I(N(UQVWUMCD%H#\)R%4/\)Q- MDCTZ<+//=\[W[UN-HRU ;&D([;'R+L;A3!&=&4/>>Y] WURZ3!@2E#CX MA5!H!RJNF!I/*BF:N/V25^9WL^J*H_-X(M\@H,^+I:7WE%$L+:R[B76$>$FE M0#:V(@OOLF]DR3:?=>^&24?<*>+=%[/&W3"ANU\B@SPI>PMWPVR=?KS;0X#Q M[/( .73EX2"\MEERS+T-9^E-/#FQ/IV]\V9RL@\N$IKNW@8LXZJ#E:>XBD%- M 5'%Z"M#.MES;@Z?U^TYS)QWX,O[G%R9"(*O<./.LJQ8= ),FIO_DKF3<*26 M3\')1JF$E/*BD$N3/:+1'::NP2BWG-9'BN,*3#OZ=S5K ^Z1"7,Z[A83,B"&B1T"\/N#DR3HVL^^?8XRW," M.0.\=IP+PJV%:<\.-KLAF^]&A);@E%!\@/@U'SJ:N+?C #HS8>KCPNA[R2/V M6 %[*-\UYSG1L#0!YJ!G5URW@+SY]\PU<0@BK^M=+8'FWRRQ.;_UIS*RV>7\ M&%U-SM<+$9PYX/=4^!NR WXCC]6!(, J!3/K@/-0Q;Q:VW5,0H6, ,%I5S$, MX0"I&!8GX%CIB&__3DF';6)@77R6#U' )_!8;(MBP4??8_'0D0N[.[,+F:BU MQP$73J7GL7C/[RQ]S_V!TKKD/;A6BKOH=>D1"2#$RB*(2P^M&=*PP<1G0 M2.\GAA86>S0K]=R)"YQ# 8 &*_WQV6K=OZYFPFN;7FR%5F[A<8JA3#MT!SP% M@VUQ\\AXF'@@M(OO264"6V ]=;6NORUU<_+]KYQ5B@E)#L\JXEJQT00QBN]0 M(4&^1M&M3!=+:+ =,Q-$401-^"U:H2%NL:=_0@Y_RK]5I_W;H/=4U'Z3U:Y( M!UGT^3$ZN']E)2;N1EJ0FY9G4]/IVEZ8=-$)N17'7LBOBL*/D*B&J>80 MFYOI:=*,LS"S8XB^84%!W@7IC,=A MQA'X3?N)[28*MK #[D\XY&>'0][O2&+C]--5I7E_YUU<_,L'QL>W56:YAW4S MM29Q^#N.'-^773$I=#"=SN(Q5Q;K$ =[U)2Z >6512H" 66=UFB MBF')U>8VG0,2>V.]"@=B&>KRE9: I[BL:SGD=7O+]:6!LU_/\YS<(!*Y=7 C M,KA!L!'[)6&PW,A_C*5^R U>YA/,]_S6VW_CROE^ 6Z):]?[_?47;H17LM;NSH>EA9Z08OGOS?+1I(FP^.[)&#&L!$_=H;< M8'TFVA/]$;&(9&[TPS<.P'L3U\;QWI*UV"(AQ"ZN$JJ/KG[Y0C2,^")!O/OE M8'1>FM^G2K$A(C+5P #PR$ M+'@C2)*_FDX( ']_8WG%%^$5CELBY>\=V1^_0 ^?O9X\79Z<#VJ5VZ[]5R?_ M6GMZ^=QL-KHGKY)\^D@;[.*Y<4H_.QDJQQTY3S7RK MG-EFLIYX9U<[=YKTO.Q(Y&75]>TZLGSU_Y9 MKC]XO##ZCY=7&-]JQ2=-O\@54BG)KB[TD[,AEDY(]^3KY9-MWN3K M\L5S]C5M/:E%IY!Z[EY\OFPXVOGY\%*UK&92K5VI=JWS?&:V\? R^?QZF[WM M*2??K^3[)^WL^-M+)UUK6H.+:]6IYZV;>J/!+B]ZO<;)1?[ZZSTC7:7=+SP< MDZ^GM^0^^6JJ7_^ZJ9//Y^?)3+-0=['Z5Z9X3\_^8H_VM\QC(7?V7.A_]$C_ M_U!+ P04 " #2.?Y02%^:I!M+ "K+@, %@ '1M,C R-C S.60Q7V5X M.3DM,2YH=&WM?6ESVTB2Z'=&\#_4>MT]<@3%YBW)UCA6MN1NS?K06O(XYGV9 M (&BB#8(L'&(YOSZEYE5!11(D((H'J"$W9U960(*65E9>1^G?]Q\^OBV6CG] MX^+L'/X_P_\YO;F\^7CQ]O0W\?_AK[_)/Y^^^W+^+W9]\Z^/%W]_,?#<\#5K M-L8AN[%'/&"?^81]]4:&6Q._J+%K[MN#%_ BO'JEWAL9_JWMOF:-%V]_=?O! M^,WI;U>+'GG#0OXS/#0<^Q;^Z=NWP_#%V]-W;R]^#NV^';*3DWKS]+=W;Y,KL.3EI]_9]=?W?W\1CEJ-5J_1/K&:_^8_3TX.F_;HMM&L_SF^?<'./M[\ M_46N!1<]DA=I;UB\&#S:H$U_^/*577[Z='%^>79SP;Y>?+PXN[[(WOV*GY'H MMEV+X_LGXW #.[ET[W@0>CY[#RL8)BQR8P\&ACME_VNXQJW!#MJ-UBMV?')T MV.CUCJL5>/0'_>7?H7CP?[ACN*97-[W1&N%:^T8_<:['_BPP?UF%?>1 Y M8;")>_%0/-V7[SQ]]? M-!N-7UZL"N=AZ(T)UO@7?2\,O1']#A!Y\U6M?,?]T#8-1VT&7D0&?7ISKIZ8 MV%8XA!?KK:[MOD QD7^\\4(XNZ_\CKL1 M9P,@\G#(62".[2]Y;!,C8"^[Q[UZFXULQ[$]V*G!+&[ZW @X\P:LU65C[B/R MZ^R+"W^$]X/0<$-F1K[/77/*^D9@ VKH@T@EXHNPB&.[W&*MMEJ!C7T@*-]V MILR")T(/EO.Y%9DA?)C9+C.'ANMR!WZ$-8!939D!P#K>!$"U^ C_X1.AV>XM M&_C>B/;T_LL_+\\/FR=L# _PD6W6TRCY[>8K_A>21:;H6'J,;UA^B5L28A8A M7AB^"^<5(!6P8&CXG!U<7%V_$L1WT*@WVZ_8@4_,A5NO:LB/7S;JC1-V8%A_ M1@'^LCS1(IWH>R,8TLTT\0?^5V3?&0YS##!"(+;)(3/@@"VP5ZH M,+N 3619H :.'1[RDA,5B59NAK:?**&DF"K] UF%&0I6U$>B""=H![SL]1IT M["^/F@VE])!ZY/!; [09H?O6X'W3B2RD(E_I4*AP6#;:4788 =^J5G"AB0T$ M"EH1<*L(/@?L" R/)=I)35.#0.=Q:$'/_+%;RMJ$Z?S[UXN+SQ\N+SZ>U]BE M:]79P3\B9RJ^I*3 *]PQ.V0IDZ-:D??^$G[G@V)@X$$>?/[7]<5K=O'Q[/,K M.%7+F#*E-3 ;A(^\U\ UA$P)%FF]J-;"I^OL!OX&@@8>@_V8'-X;.$ T<+#X M5J*:P@O+5%,'",0A ?<0)55N^6\@-5W7NR.N [0!^QEX0)0U05T@VPB*.Q!4 M#"47<*AI3&Z!I&[\PL S(RGS$!N.Y]X>HAR$Y2V4>5,VB%S+0*%I +3XG!7Y M1I]DH.2J\"R:S?4B&_B__A5YX9LO(,I#;HS8$+0("_9P"_N"&^4:=_8MD0OB M!$X-#'OW%I:'O<*!B)--TT.=?1_:J"# DCHUH'X: ">S!\#5:'%C,! \I0\_ M$VG0 1"A\ 4D H^J(S_TN8.@@: A)@%;Q&_RP8#L:A0SA@.6ES5E4YL[DOD0 M*8.:XRI^!*P,J1@E$@=.!/P#J$8(1Z4PW<(J^$QR)8"P?]KBK&L"@]5*8-@6 M^P=\GEW;HQ%L!ED3#VRTK87>-;3Y #@A-R/ZC#< 5,"R(&@%\=:96.L[\D C MI<$1.:*0EJ\C<4\X'-==(DPM<1SSB$M9A;B>X+*"I]-- 5@MCKS31Q-3MS#A M)&Y];T):@^\% 1%"859/GS'Q9.$0R#+V$*B M_,%#:<\@GT'M$ZUBV)KADLHK-!C'B%QSR.7-Y$1!L!Q0DU!B 81$V97Z;9!H MUX)L80]VP.X\(!^DU!#N1YV=618=.I#X- .W0$L.42FP#AN6= ' (# N['" MA)@A=:M:2>M;P&?MSD;< MGQF"H*:D3H(SHA40^+87!0[RV=$H]FX(#Y$D#B!@V[-JXAO:ZX#"EYUNHF:A-/Q6OZZS M]_$U$8176_#@)M!^M7, M5N^'+B!5R5-Y%'C@HRB,\*H"_W8Y\%'@RF+-3(2D3Q>9S \^398'T30!@P7] MUD:?]".D ,%J-6X'/ 26!1DF.,K(@&.Q_P/*L6$.:;$IJ!_P'1"1X9"(2#)5 M9-P!K& QT!FX[TSI[@OM!K9U!ZP/W7NV&11:5S@+M(,'^LS4Q(!O MFS$3=0 M?@XB1^KPP)@%==\Z7E\CJUIR3X6\96@1C.CV#$%Z3VS7$FJ!N"P@6F:NQ%&7 M'"3'"<7;F?RI6NF3L/&$:Q35&#AX$C&^L&R0^+434B R/%)+TJP$?X!720HE MJ56"ALP=R6R,/ST?%4& %O^M4 #?@X>1 >'Z8X<\OR \T/ZI2._"H<\E&(HIHL=9:@BS4A65E!KK@YBR8!T+ M6640DBZ@Q!519PWOOM$'G-^!T$?42 4YQ2^$+(>+8$P$+KP@5':<+2&(=44I M2?#2UO > -VY*%3%!U%RHI(D!+CGP_;'<**Z&1D,P6@@;Q6RG*D"&/@*:FQX M*=49R&_B-1\)=\: :L&C@ ? "E ? LU2O;)\$WADN,&D ([ SW((5@S=UK3 M+G ,L103@G$!@!81>2"4--^+;H=>%.IP ?[A%WTPFUTD1=R75$1!#0F(Z%;B?DX/Q50-$C[UR0G%' 4?^;,[GCBXUZ&5C% MPSGZ$>PP-KV%>C4%W!6:F\5+_=?A(?N %L)K=@4JY!MX_J^(@\T"R[+#0YE2 M<'I^^<\LGT&SE>$TZ.'O0)( *XE_]\Y!]UH3/DZB )T]N=Q.\IMR-9)1XP!@ M4S^]8=+3@XXIX:HX#$ L":3A=@W[&8Z!@#/T& VW[#/8$<+Y'_V$.--_:7?U%OXET5?;_^2F6:A@ZR[ M@$Y_@]/,.-@Q@'#8!V7LQV&? [T#5(8S 24][;_K91PYT@'L=CZ1(AU437U9 MWR7N7E!;0:_+N[>GW]Y^]_P?R#S?BQ@"7?QWAD,6_O60\_#TMV]OUQJW?O$V M-BLT+TUL#Z,UB0#)N,5(!$Y<4/-#- ]^D)="1CS R M2(F&I"3(VIB,R'C#Z M0LUR+:K$=3TJ'"7>*C@:+ BJ$FDI?#JWWS4 MR5P8O9+J7E]01[42('F(,*46RZK-(@0^\;*IZ7(H[H1'SO9!2,UY':4&$4O1 M"9\Q0&6X"O3/S'A5C=V"!2$]!B^[W7I35R-Q5T V W(1@:(FO ?2SF<+S7R, M^[N 5M!-T_:>YQ"U@KUGV6$, W!P!_VLH!":PH_ ?P*)DG)_%OEG\:'K5/CQL.&8D?65&(/4CP.4 ,2(11V<+I\#(82>7 ME7ZR0'BKECA_$]U 7E;!%Z:HXI$];(R\"*!%B$ -UT$B+'ONGY$K'"3*L)9. M%?E9"U"\OLNQ!1>)8)>"3+Z-+=CIVCEC6N)A;-\>3%^\_-C(LKKMLD3QN48F%7R*_1^HA.N(R)T%SJ[Y^&K&U9KO>I7>S MU0Z1,"5#:C*4]CM@7ABR,D0*J <$(0^488(DY@4J/]('V;-WJ$>3THWV6^)> M_#/R[<"R3>FF56H_GIK0^X%_OO=&(QML2CQ1_(1P]G +?3#LQL=S3![)4(?* M6.OFZ.$#&+2._9\%)!$S[AD?<2RG:NR=;_S'=FJ@2*4R&-B22%L%-TWP*. T=B@ MM5F"J0!5*0'P!AEY%U^O6# -0CY" 3^$"RX%O-!*AT(K MC9V8)%M((:D)OQ"H97V.RPV]0(9A;XR0LKTQ2FI@-NJU\$(&U(J_,LP(*Q"NH3WOP6I MB'C?IT3.D8=V3X29!;!RHOE2-@QHZI[W Z7$Q/ MXN83[B@/)BA@2 B4;V_< M2M.8- .AA6-('Q5PLDO!I@BY2[I\$NA YJ"2>21MJ)0=_#Z"S<[Q2BPX * M%E* C>U'8UHQCMIR[3O5B@B3"=GG@45BFS]0PED6Z:BXQM@+,:Q@.'KJP@1C M@6BF@YW$]S#X"F;%7+F S-N)ZP:^O7V]Z7"O,OV F5!NO'+(9R3!@_Q8D 5/ MZU%56 MFYZ6)I.!;!--;_3IBWT<->J=AS[D>"*&F8RY80&V^U6O76HHTWCV-P M[_L>2SYG_)2QVK!:$=]HUT^6A^P2+\]G'@(G#.Y+0I.GUM9A%PGP32(KS&V* MR ]"J2:S1(-.0S!A@2&3&ZK=30",UVGHZS"Y3 R5,5+A>]P1[;S(+KW3=V_G M0N7G=D '?45TB*R6D@IGDQ4 AZUF3 <* ;$;+LGR$5E]=YX3C4BHU42I2CH7 MS,'8F"]$%-!YY Z,.Y!/F'VNQZ,6W*@:>75MR@?P!H, CA%SRMPXPT@HKZ#( MU-GW!S$5$L?(&- Y'&\=#C:NXZE6T#$GMZ=NYT2ZV9)T_#C!S?@!:)'I*C+B MNBSI326]!$)<&D$<)9;Y P!YM:)%3N-@]$P]@![*FTF:)7>!"NDNCNC6V;7>"92/SL92(_ MTY,(*;;*D.(N0HJM,J18O.N2(7V F?K&F$*]@.FL4.R Q M\DH>*2# "MFNY-$*2!.Y4ZWL0/"(Q#4I=@ /#Y<[\>NVX1ZFTHZ2Q18)HYJ& M[KA<1,\__AW.Q![[&+?0,D8Q>XO+5>$>RH7O8@2@*N%$XED9^Q(5"QA%%-KG MA1M.3?ZKSV_)#<8^>Z8=&O1O"J_-;EZOML(2*CA?PS64_ NIYF966RZTD'OW M5LLC91\B^6!KPYY^-48@ $1$=)'>V&P\0F]<45-DLXHB6D);N*^]K/NJ M]$1A",UN>:X 1I9WRS*'V4N%83Z9E#B6AZ!2\%18('(IBQ*Y@>'\9+Q^EAF6'Y;(4\*>N2B;SBML912 -62;)M M]^D2?(U&6!L">!'T?SU!9IPMOCHMW,5O6HCOI!.Z0'\-&R&8#S,5E4+*,<]'"@K509%DE)O8JWGQTXY+..T@YM>" M1:DZ&4I6PPL%BT<#^$%6^:7J--AD:&-Z-)PXEH(DE9$BCDC7UT\<=2)9>%I/ MFJ<@1YH%3&>/L\I!M1*S1U$.*L&%A]NZWS3EAR[TR0C_+Q#HP)89<:V3E*,9 M-JX[?G6O<"PM%WA TQ[-EYU6M]Y++=SMZ![E9?Y4=-OJKFJZ:XGP2H!*VM/, M^J1K\UUJ="$E]7Q19?_TFONP+#(2)(> M\NR7S5ZK?IR0MB0OO6H6B4/K;J(;@G%8''NI1+["!(IED?Q&35 2XKVS?2PX M Q9$772(7"@<>X?F*]&R,4V5U,Y*)BWT*]4 W)M-!B85?-@#X,#VIBNKC.+1A+P)=(!^=6H5G*%]_($+A/^<18@#T<% MS?9%SR*@A-"/),L6=\NCFE2J?,,&&*!*^QC[3[1*:JG4U,C['A")6%ZVFPG' M6?8"POE>?A-+MGR+^A0L_8+(G>5,2+2$\\@V!ZH^44_KDBIL3??2H2U(:5UB MG>1M-#3^BFQ?KVSD>LZNJ$ CGV>*EFBQ(%D5W,ZZL)93B+ 2%== M8\L[BT5CP7G]6UA$TA?>;,2LQ?&;20N :4T[\305PCM!;%J9,=)CI&5E/Z)* MJ]&,5MB_P";6[(J$,0FB0";H!Y2]B\66I+!@:(&2Y8R1+$87ZC)IRQCMHJX% MA;[VGRD6CN[8()S)#>C<=PEDE@'5AZ3546"@1_DNT"R3%[%Y3)TFU ^Y!5KA M+?6N(@3+PU(@)]W-EGYEN28G]3CV!;G)X4QV &A'2?K"Q$@NNOQBM;(H82:- M$P4G91SDRXA ]D(P*7AF/KU02TNX"C:>M"GM3U[D6U4QH'5XBW.+^Y%-#51( M0T8*$LG"W]$I7DN2E0M-T/-Y4YCHB'%3XA2NYQ[^?G9VI9*H7HMZC>+NYTRV M<]2S5O)DQ[1[]68LF.;">WE\HND0 MZ'1;+NGG!7W,_I7CVUBHNV"H1H@-!")5IB\50^.G7(AN1J(L+KH;]UP-Q9T8PH\1UH)W!Q=3V;4D&G3:T_XUZAR0O5BJP@O3M68]XMDD1Q0P5CU_BLUN M$!?Y9K1/SRTN77 8D&$+2ZQWJ\4;,#]V7E$0. M9@1RX#VL//UP^?GL\_O+LX_L]V^7Y_#CQ08J\S="!0L]6;5T4U&6ZLD.UG7P MH"ZEV"3*YUFIX#.QB1I;MG)7K=QH:$I5TEZ06A+*AD89O8O:#>%G:^C2-^ZI MI*S8.&"FVER*TFY128I>;V&O5RMN-.H+A,49-+G*J^\I9Y\)WHCOZFDZ&H;( MP$]"2C&FFBV!J%:Z3VPX\=@(R&48YS7$&:'P-+:CI-8*4F^T$CTL3'7DQX?U M\P3S3R(]J,.%4(2ZZ>KKC5_O!37?LCG'Q;OW9]-_$Q'LH=<)\$N4F]&D-V_+H! MM[,^JH.R:V!FF2L:W=9419%09:6'*>G,&:A^#'_B;V 75LH#^!YOH8]0"O76B=@J0(#'(^_!;:O ]#,-Q M\/JWWVP)6#T9TT++!B1 <8&+.]+U\9=7XFJ+* =8%*)Q1=SK3(&END]@Z ' ME56DU%3 N /Y+IQI& ' VD7LPD==-JC[Q9ULC1*G@3N>*8VXN&$![O9O@=K- M.D7T-NAYZ44^>_?EVPVU9G[_9=_O:ZK/-'8"4:DY:<^QNH3DRY-!JD#/*@7: M^>%Z$X?\?K(Y7J#\NZK%;HAM-S$*I;*7M#9],OV#RS O"@OXF,M.,'@989<> M+,V2O7=[W4.L-JA60!^U0]"=J0P2U'[/%ZYDV=I6)>9A")D(4VZ'4H:2K\K" M)](&XF0A,J4==-H$E =[*U.O1,,5;*T3!?Q0^ .J%1-8322[XR; ]VH-X'%\ M-':\*4?XS\*X@'/"?_6#OR+OC<\UKP*"<&>KM%:)'ROIZ88Y'HR[/G!&!,FQ M!V W8'VLZ%YDW9%S.W.K-<"N-W9XPKP $A[6V4?L$"*@AN.93"8:G]FWBZON MZ'N#VC!CRM\'4;%[^-'S?@BE4CX3[(,>?C-G E'&!'G; M92WRH2-W%L0[(^52M7B4#4"1/*ZYT#U;1V=*2,"O(E]T4CX3WK_F2;M-A!,_ MW;S(>/I"91HFKW78@?[;5Y0B$\>T5&DFZ3_J?D& 40$:$U#0HN;B58N-0_G9KC M\GX8]WZ2#<_CAO2DGJ12&6J4K!,7G%/ /=9FT+\FX1;Y=?>JBA8I*VZ21N:Y_A>5]9/*15!MVQ%&D5*N@NJ%=O-]6'P;,.07 M=YP5G!]G?(4I(I/Y"D$0C<:*ZA0/2:.8%"-*99QJGF^)J_@P002\XR0YEEU4 M85A*NJY6Q"(U% \AM;1V#?$+^->4]A%$?4J>H(;<0T[;P$@J9:N(N*EO!S\" M%81U1;2=F;9O1B.,]YI$.#8WPCTX[,DY"=H&_.P-$4;M6!\ M%?:-IITOPK32)/0DDT)A:,C434I07XB&.KL!?CAHLB-J3&4+8XI-M:)2ESU'I(S4X@S6FD8.VL"" MFDP74OF1MYC)BOG""56D)A[,1?DEQ-@+/=6[:^WW[4$NZ3F_\]:ZMBS0)%:> MOI/E!4_W=U&O91L%>I":'/ #8V0[T]?+4?'B+=SEVV$(NJ=%78]59K=.#$2Y MVIP&SU>YX,&;.(WQA@;G+N[ZLB)YB/^N)PA2@R@/%5:?4M.?G'.:9OK^I*L< M5%.4.ZZ=F6Q0(S3S(%V71^X$2CO#O&XTF6HS"DS(S:'K.1Z*9K%04A47R(ZE M^/RAQ=&&L%1)1=D$;-NDH(E5C<=32%RV!U3>D4AX=K%HI6][5$H[8PN7I[?+ MB^S.ZNG"T16-QYB9,S2P*XQR$Z0& %#+31LL#HORT>>+34W/]W!HDQ\%[$#9 M'J]BG4+>>66+E%2P;2H@I58."1.>(T>V/=9T?J6&7M50GO*V3]G "QY2H%]D'5%AG!<%L6O2-'S?%C9*@=CRR@K= M?9C/D0O3*7-A=I$+TRES839#\R47%#J-"%K*@8!?*31]+N?%F%1:?*M\?Z6< MVK$VHMJAZDYMH5O(8QQ$#H6^1 4*3Q72B_LP/Z MZ55)!;MU,:2"%MEF@S)@--*)=50Z['A&7-++,ID18)BFST6Q#Y8H"#>V#)!B MT63@F3:]&ZU[8.*7/U^!L: XPR$&,= D MU),4OX@L*\&C,9D:@WHBD@4G"/*\/+MMGYW6U%QU4->5LJ%&8B:/R)U# M O$QO=YV9.TYYA?,^?M5XO'+3O!E4>TP_ I-3Q7O0ME%SM@X*;H,N%IIB;JT:QXN'1,C[.BDLJ,T';@<4+6K(^+4]&@VR543G91P1)HO MC@(2*A/][L*QV4?;<::RF$O4 QS0KU[-.A11$&(\3;9_BPW4:D5XC9)Q1*)K M*C:<,1SLW(0C+=#BG7%0)JZL5',:BJR,@;OSV&RBK'9*&#ZX^'KU2HW@BE,R M,?M8JRU5Z353-2QI[V=H89&F$;<59?INC;[J$2OS*=EL.B5V(\04"UO$&(2_@AV>/B_=#KPP_^Q@>TD5)).+<=GXD3R9%YF MG9TYF$)^.XPG81DA9IE*28\CL3!/CT2'2"9%;4!A@'([?$ZYJWVN2$1_@I(Q M9;TD[!VK7(AL(R%W$($3KCV@9FJI#IP*;W.XGDU=G>G_)K*[EB:S4K6635F! M071[RX-<>;6J5D#UHYDKIV:7F)PT54GR>+E(?U) V/_AU&W.IL=BGV\?BVST M5.DHF4>R!!I1G(,=-GSLUEN;08O(P-;Q\7KQ0@U6!6*^8VH I0X95MF+5L, M;!L^(9)><+AGRR 4J -41<$")& S%^,'YK(YE.*D)D#+@)//O4&=?9!7!_V5 M=PF@.O%GY(_KY#X5*KDL:0YMG** F=#P@RR(H F)=#<]8 1]1]1>1:KH#'/6 M:6Z@ '!$AT<4B7V=L=F7UP8U(7HA0M) MU0G4Y5%@#W>O2AA$\QOL8(BS1\60GB#F2!@A="W!'OG/<3R/3T(7PA(6P66[ MF)TJJ;Q*LI%<9!@@,')H3@R2?6P*:S<%7\% @-* MH1Q80'O!6U119=DW$2:)>U9\B$MV/LDN&*_WH8;LN\A#C5MX))5'6C./"-N2 M!LI_$21=&)**H7@BGYI)+QL7B<^I1J'8 DG^?>87\P]BPZ4#T7'I%4V5T]^Y MND[^5:U@6R5M2."0."%(($JUUE[3NS+-_5KFY%'Y,\=D76V?]S34EYWZ28O% M&+M,T<;B\?_P=!;IC*"7EXPZ0H+&JJ0.%6'*!BNR5,5/=5(1W5""N!T*^J_L M#71"V0S%*=U(:!5+:(]X%=#G(')$49.LS*]6^K)\BFJ?4'? V66W6%C,?6%8 M8#\K'(Z;KM1*>BEK_*L^TZ:P&R8AC2S4"F)?. M:I8MRK0PJ4S36@+,5.>*.0VB;^ T4363:LKLD+T,]=+]GFOB,SOLC=PQ](0B M8%4B):K3XL(DN+6OQ+F@[$))TU<-QJB; %IO )ACH$\4S#P'^X6KCT:!C)S( M>!G5.Z<:H"857'I=)8B@ UM]5_8AT0XE9?X ;EJTYO#RM1'/G2P:02!KQ0GS-TW@4 M37TB=\9_FXPV2)74JI.=Z1.DIEMDD+M0BU(ZBB3>6$]!@ND'0+/H7:3#T6^% MY =J1;B5W]&3 ?NGYOC)MJ1&"0P3-Q"Y!A"V2!G'TJI _)0TO4S(.%6?**M MT:[UN6Q\K\P2C5.2CA=)T=TR*;IPU^6[FB"/"AG%36>ZQ*D8J.RD0+Q#-(Q+ M.A_)7A!IWV^B?<=F2-QE3,MN%4)")KC*1F24;$B&/ZF3KM)"E-I([A4!#YC2 M(/I1[^C+\0C"P4W34N0<]%E-W)/ZN81*N *5B6MAD>=(Z?6H]_E6TBE"J([) M#![ZJ*@"QJ^JD7)N$,DZHG!.DTE\]DFEOZ[TDF:C.E7,HR[&5(+#?>OULKA) MT]E,;M5[.;=#:RNYETV;I-&NVP1RK >U"TP43D5(&M&00F G+J&+M0,7JEBK&3JZDVB,,N<2=^"D:\V@F\C^G)\Q 6G2\] 2%8R+T%YWFAF$G" M%.=$0#;GSH_),68TN+<)KYM9-('@_1=$S.>_O^BMD+&3=4+W"=&;H<\Y^R2: M)%]07.T?D\6ULZ&6Q_N/]TO#UL M-4]*;)6TM8>TE9,= IP UZWO1:YU*-OI^[?]@U:C4VNUCVNM;O=5!LN4ZD?G M^$':AQP7L,#F:F89FYEG=>][64;HRT6?S3!R,VV_[G&OWLX/>V8;PF46;]'W M?W3>\?Z;M5:G4Y_C3@7RXFSAR\<([/;;-6/UH"(^[#\ M"$;X?0AV\0*%<570WGLTAT*U6]8&Z+[.$G.Y+\/*M)>']%=X\P&?+#=6;FR[ M&]NL:]59W+'D$)71AD>RJRN_]9[0.[OK8%>6IMDZZ]3EM>'

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end